
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference taking place January 11, 2026, at The St. Regis in San Francisco, California.


















